InvestorsHub Logo
Post# of 251799
Next 10
Followers 829
Posts 119621
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Monday, 10/22/2018 1:19:13 PM

Monday, October 22, 2018 1:19:13 PM

Post# of 251799
MRK—Keytruda data in first-line H&N cancer from KEYNOTE-048 study:

https://finance.yahoo.com/news/merck-keytruda-pembrolizumab-significantly-improved-143000250.html

Keytruda monotherapy bests chemo in OS for PD-L1+ subgroup even though ORR and PFS were worse than chemo arm in that subgroup!

Keytruda + chemo fails to meet prespecified thresholds.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.